AAAAAA

   
Results: 1-21 |
Results: 21
HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers
Authors: Gorse, GJ Patel, GB Belshe, RB
Citation: Gj. Gorse et al., HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers, AIDS RES H, 17(12), 2001, pp. 1175-1189
Cytokine responses to human immunodeficiency virus type I (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120
Authors: Gorse, GJ Patel, GB Mandava, MD Arbuckle, JA Doyle, TM Belshe, RB
Citation: Gj. Gorse et al., Cytokine responses to human immunodeficiency virus type I (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120, VACCINE, 19(13-14), 2001, pp. 1806-1819
Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus
Authors: Ray, R Hoft, DF Meyer, K Brown, R Lagging, LM Belshe, RB
Citation: R. Ray et al., Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus, VIRUS RES, 75(2), 2001, pp. 147-154
Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children
Authors: Luce, BR Zangwill, KM Palmer, CS Mendelman, PM Yan, LH Wolff, MC Cho, IS Marcy, SM Iacuzio, D Belshe, RB
Citation: Br. Luce et al., Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children, PEDIATRICS, 108(2), 2001, pp. NIL_22-NIL_29
Canarypox vaccines induce antigen-specific human gamma delta T cells capable of interferon-gamma production
Authors: Worku, S Gorse, GJ Belshe, RB Hoft, DF
Citation: S. Worku et al., Canarypox vaccines induce antigen-specific human gamma delta T cells capable of interferon-gamma production, J INFEC DIS, 184(5), 2001, pp. 525-532
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers
Authors: Belshe, RB Stevens, C Gorse, GJ Buchbinder, S Weinhold, K Sheppard, H Stablein, D Self, S McNamara, J Frey, S Flores, J Excler, JL Klein, M El Habib, R Duliege, AM Harro, C Corey, L Keefer, M Mulligan, M Wright, P Celum, C Judson, F Mayer, K McKirnan, D Marmor, M Woody, G
Citation: Rb. Belshe et al., Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers, J INFEC DIS, 183(9), 2001, pp. 1343-1352
Mucosal bacille Calmette-Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses
Authors: Hoft, DF Brown, RM Belshe, RB
Citation: Df. Hoft et al., Mucosal bacille Calmette-Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses, CLIN INF D, 30, 2000, pp. S217-S222
Prevention of otitis media in children with live attenuated influenza vaccine given intranasally
Authors: Belshe, RB Gruber, WC
Citation: Rb. Belshe et Wc. Gruber, Prevention of otitis media in children with live attenuated influenza vaccine given intranasally, PEDIAT INF, 19(5), 2000, pp. S66-S71
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine
Authors: Sabbaj, S Mulligan, MJ Hsieh, RH Belshe, RB McGhee, JR
Citation: S. Sabbaj et al., Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine, AIDS, 14(10), 2000, pp. 1365-1374
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control
Authors: Longini, IM Halloran, ME Nizam, A Wolff, M Mendelman, PM Fast, PE Belshe, RB
Citation: Im. Longini et al., Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control, VACCINE, 18(18), 2000, pp. 1902-1909
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
Authors: Belshe, RB Gruber, WC Mendelman, PM Cho, I Reisinger, K Block, SL Wittes, J Iacuzio, D Piedra, P Treanor, J King, J Kotloff, K Bernstein, DI Hayden, FG Zangwill, K Yan, LH Wolff, M
Citation: Rb. Belshe et al., Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine, J PEDIAT, 136(2), 2000, pp. 168-175
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
Authors: Wright, PF Karron, RA Belshe, RB Thompson, J Crowe, JE Boyce, TG Halburnt, LL Reed, GW Whitehead, SS Anderson, EL Wittek, AE Casey, R Eichelberger, M Thumar, B Randolph, VB Udem, SA Chanock, RM Murphy, BR
Citation: Pf. Wright et al., Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy, J INFEC DIS, 182(5), 2000, pp. 1331-1342
Correlates of immune protection induced by live, attenuated, cold-adapted,trivalent, intranasal influenza virus vaccine
Authors: Belshe, RB Gruber, WC Mendelman, PM Mehta, HB Mahmood, K Reisinger, K Treanor, J Zangwill, Z Hayden, FG Bernstein, DI Kotloff, K King, J Piedra, PA Block, SL Yan, LH Wolff, M
Citation: Rb. Belshe et al., Correlates of immune protection induced by live, attenuated, cold-adapted,trivalent, intranasal influenza virus vaccine, J INFEC DIS, 181(3), 2000, pp. 1133-1137
Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults
Authors: King, JC Treanor, J Fast, PE Wolff, M Yan, LH Iacuzio, D Readmond, B O'Brien, D Mallon, K Highsmith, WE Lambert, JS Belshe, RB
Citation: Jc. King et al., Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults, J INFEC DIS, 181(2), 2000, pp. 725-728
HIV-1(MN) recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1(MN) recombinant glycoprotein 120 vaccine
Authors: Gorse, GJ Corey, L Patel, GB Mandava, M Hsieh, RH Matthews, TJ Walker, MC McElrath, MJ Berman, PW Eibl, MM Belshe, RB
Citation: Gj. Gorse et al., HIV-1(MN) recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1(MN) recombinant glycoprotein 120 vaccine, AIDS RES H, 15(2), 1999, pp. 115-132
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates
Authors: Gorse, GJ Patel, GB Mandava, M Berman, PW Belshe, RB
Citation: Gj. Gorse et al., MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates, AIDS RES H, 15(10), 1999, pp. 921-930
Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of alarge randomized, controlled trial
Authors: Goebel, FD Mannhalter, JW Belshe, RB Eibl, MM Grob, PJ de Gruttolae, V Griffiths, PD Erfle, V Kunschak, M Engl, W
Citation: Fd. Goebel et al., Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of alarge randomized, controlled trial, AIDS, 13(12), 1999, pp. 1461-1468
Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies
Authors: Gorse, GJ Patel, GB Mandava, MD Belshe, RB
Citation: Gj. Gorse et al., Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies, VACCINE, 18(9-10), 1999, pp. 835-849
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults - A randomized controlled trial
Authors: Nichol, KL Mendelman, PM Mallon, KP Jackson, LA Gorse, GJ Belshe, RB Glezen, WP Wittes, J
Citation: Kl. Nichol et al., Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults - A randomized controlled trial, J AM MED A, 282(2), 1999, pp. 137-144
Influenza prevention and treatment: Current practices and new horizons
Authors: Belshe, RB
Citation: Rb. Belshe, Influenza prevention and treatment: Current practices and new horizons, ANN INT MED, 131(8), 1999, pp. 621-623
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
Authors: Belshe, RB Gorse, GJ Mulligan, MJ Evans, TG Keefer, MC Excler, JL Duliege, AM Tartaglia, J Cox, WI McNamara, J Hwang, KL Bradney, A Montefiori, D Weinhold, KJ
Citation: Rb. Belshe et al., Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers, AIDS, 12(18), 1998, pp. 2407-2415
Risultati: 1-21 |